NASDAQ:HARPHarpoon Therapeutics Stock Price, Forecast & News

Harpoon Therapeutics' stock was trading at $13.07 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, HARP shares have increased by 26.9% and is now trading at $16.59. View which stocks have been most impacted by Coronavirus.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Harpoon Therapeutics in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Harpoon Therapeutics.

Harpoon Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for Harpoon Therapeutics.

Harpoon Therapeutics Inc (NASDAQ:HARP) released its earnings results on Wednesday, May, 6th. The company reported ($0.51) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.40) by $0.11. The company earned $3.30 million during the quarter, compared to analysts' expectations of $7.58 million. Harpoon Therapeutics had a negative return on equity of 53.62% and a negative net margin of 681.41%. View Harpoon Therapeutics' earnings history.

7 equities research analysts have issued 12-month target prices for Harpoon Therapeutics' shares. Their forecasts range from $24.00 to $36.00. On average, they anticipate Harpoon Therapeutics' share price to reach $30.14 in the next twelve months. This suggests a possible upside of 81.7% from the stock's current price. View analysts' price targets for Harpoon Therapeutics.

News headlines about HARP stock have trended negative on Monday, according to InfoTrie. The research group ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Harpoon Therapeutics earned a media sentiment score of -2.1 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news about Harpoon Therapeutics.

Harpoon Therapeutics saw a decrease in short interest in June. As of June 15th, there was short interest totaling 211,300 shares, a decrease of 33.3% from the May 31st total of 316,700 shares. Based on an average daily volume of 150,100 shares, the short-interest ratio is currently 1.4 days. Approximately 1.5% of the company's shares are short sold. View Harpoon Therapeutics' Current Options Chain.

Some companies that are related to Harpoon Therapeutics include Beam Therapeutics (BEAM), I-Mab (BDTX), Legend Biotech (PCVX), Sorrento Therapeutics (SRNE), Regenxbio (RGNX), Mesoblast (MESO), Sangamo Therapeutics (SGMO), Cortexyme (CRTX), NanoString Technologies (NSTG), Coherus Biosciences (CHRS), Adaptimmune Therapeutics (ADAP), Passage Bio (PASG), Nantkwest (NK), Translate Bio (TBIO) and Compugen (CGEN). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Harpoon Therapeutics investors own include Alector (ALEC), Editas Medicine (EDIT), Gossamer Bio (GOSS), Precision BioSciences (DTIL), Tcr2 Therapeutics (TCRR), Kaleido Biosciences (KLDO), LogicBio Therapeutics (LOGC), Homology Medicines (FIXX), NVIDIA (NVDA) and Stoke Therapeutics (STOK).

(HARP) raised $76 million in an IPO on Friday, February 8th 2019. The company issued 5,400,000 shares at $13.00-$15.00 per share. Citigroup and Leerink Partners acted as the underwriters for the IPO and Canaccord Genuity and Wedbush PacGrow were co-managers.

Harpoon Therapeutics trades on the NASDAQ under the ticker symbol "HARP."

Shares of HARP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of HARP stock can currently be purchased for approximately $16.59.

Harpoon Therapeutics has a market capitalization of $414.72 million and generates $5.78 million in revenue each year. The company earns $-55,570,000.00 in net income (profit) each year or ($2.55) on an earnings per share basis. Harpoon Therapeutics employs 45 workers across the globe.

The official website for Harpoon Therapeutics is www.harpoontx.com.

Harpoon Therapeutics' mailing address is 131 OYSTER POINT BLVD SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-443-7400 or via email at [email protected]